Gottlieb’s New Year’s Wish List: Risk Management Plans Out, Science In
Executive Summary
The growing use of risk management plans to mitigate risk in the post-marketing setting presents "potential harm to patients and the practice of medicine," FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb said during a speech on drug safety at the Manhattan Institute in New York Nov. 13
You may also be interested in...
Outside Pressures Threaten FDA Effectiveness, Gottlieb Says
Payers are pushing for more comparative effectiveness studies, in part, because they know the more expensive and unwieldy studies will default to showing generics and branded drugs to be equal, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
Outside Pressures Threaten FDA Effectiveness, Gottlieb Says
Payers are pushing for more comparative effectiveness studies, in part, because they know the more expensive and unwieldy studies will default to showing generics and branded drugs to be equal, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
Von Eschenbach’s Commissioner Debut May Be Release Of Safety Report
One of Andrew von Eschenbach's first major steps as FDA commissioner is likely to be release of the agency task force response to the Institute of Medicine's recommendations to improve drug safety oversight